NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report published on Tuesday morning. The firm issued a sell rating on the stock.

NovaBay Pharmaceuticals Stock Performance

Shares of NovaBay Pharmaceuticals stock opened at $0.08 on Tuesday. The business has a 50-day moving average price of $0.12 and a two-hundred day moving average price of $0.21. NovaBay Pharmaceuticals has a 1-year low of $0.07 and a 1-year high of $1.52. The company has a market cap of $2.74 million, a P/E ratio of -0.02 and a beta of 1.97.

NovaBay Pharmaceuticals (NYSE:NBY) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($0.95) earnings per share for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 150.14% and a negative net margin of 65.46%. The business had revenue of $3.73 million for the quarter. Equities research analysts forecast that NovaBay Pharmaceuticals will post -0.41 EPS for the current fiscal year.

Institutional Trading of NovaBay Pharmaceuticals

An institutional investor recently bought a new position in NovaBay Pharmaceuticals stock. Armistice Capital LLC bought a new stake in NovaBay Pharmaceuticals, Inc. (NYSE:NBY) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 718,768 shares of the company’s stock, valued at approximately $147,000. Armistice Capital LLC owned 11.01% of NovaBay Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 23.25% of the company’s stock.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.